Deals & Alliances
Pricing and Reimbursement Risk and Opportunity in Pharmaceutical Deal Making
| Publication Date | May 2007 |
| Publisher | Pharmaventures |
| Product Type | Report |
| Pages | not applicable |
| ISBN Number | not applicable |
| Product Code | PVT00017 |
Price
approximately: $2,596 | €1,889
Order above formats by FAX
Summary
This report focuses on the critical application of the challenging political and market environment within the specific context of Pricing and Reimbursement (P&R) in the process of Deal Making. The in-licensing of new drugs has increased dramatically over the past 30 years. As deal making has intensified the nature of deals has changed and issues such as market dynamics and the uncertainty around future pricing have increased in profile and can impact licensing deal valuation.
Where once a licensor would expect its new licensee partner to take responsibility for price setting and price expectations, both parties need now to increase their focus on the key price limitations that impact the deal value.
Valuation in deal making is not an exact science. The message coming clearly from the pricing and reimbursement dynamics is that traditional models need frequent revision. Health economic considerations that drive reimbursement decisions will play an increasing make or break role in new drug planning. As deal making for in-licensed drugs grows in importance so smarter deal making will become vital to the efficiency of the pharmaceutical business. P&R awareness is integral to that smarter deal making.
This report will teach you the key P&R drivers that shape tomorrow's market. You will learn what likely effects will surface from today's political noise and be better prepared to anticipate product opportunity and maximise future success.
Contents
- Summary
- Introduction
- A New Profile for Pricing and Reimbursment
- Deal making in 2006
- 2006 deals by type
- Why deals fail
- Price and unpredictability
- Deal making, the strategic pipeline
- New hurdles for new drugs
- The shift in phase deals
- Potential reasons for shift
- P&R specialist's view
- Changes in Deal Making Risks
- Risks in the pipeline
- More risk, less value?
- The cost containment driver
- Shared P&R responsibility
- Unanticipated reimbursement issues
- Reducing the risk with future P&R focus
- Current P&R Environment
- Price and value
- P&R in the US
- P&R in Europe
- UK and the Pharmaceutical Price Regulation
- System
- Germany
- France
- Italy
- Spain
- Parallel imports and the Treaty of Rome
- Trends in European P&R
- One market, one launch strategy
- The outlook for Europe
- P&R in Japan
- Future Effects on Biotech Drug Prices
- Growth pains
- Biosimilars, generic equivalents
- Value added biotechnology
- What price the cure for cancer?
- Orphan Drugs Risk and Opportunity
- Reagan's 1983 legacy
- Orphan drugs in the US
- Orphan drugs in Europe
- Orphan drugs and Medicare implications
- Paediatric Drugs and Patent Life
- US and Section 111
- Patent extension
- European paediatric drugs 2007
- Class benefi ts
- Paediatric deal values
- Reform of the Paediatric Exclusivity Program
- Pharmacoeconomics - The Future for Pricing Value
- Breaking out of the silo
- The history
- ISPO
- Academy of Managed Care Pharmacy
- Positive effects
- Integration into on-going activity
- Moving pharmacoeconomics further back in the process
- Collaboration opportunity
- Earlier cancellation saves millions
- Failed deals, smart moves or preventable mistakes?
- The UK and the role of NICE
- Quality Adjusted Life Years
- Incorporating early P&R awareness into pharmacoeconomic modelling
- Benchmarking Product Value
- The relevant comparison deals
- ENPV
- Benchmarking
- Benchmarking your product
- Monte Carlo simulationInf
- Strategic Issues for Deal Makers
- The role of politics in mathematical modelling
- Pareto and DMasi
- Tweaking the model
- What can impact your value?
- International launch strategy
- Converging prices from divergent systems
- Schering pan-EU pricing
- US versus EU prices
- A global price convergence model
- Which deal is the best deal?
- Pricing and innovation
- Drivers of price premium
- Political lobbying
- Targeting protected me-too and followers
- The pharmacy view
- Ten years of change
